Linker Information
General Information of This Linker
| Linker ID |
LIN0JLWZP
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
AU2023279443A1, Example A17, Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C45H68N10O22P2
|
|||||
| Isosmiles |
CC(C)[C@H](NC([C@@H](NC(CCOCCOCCOP(OCCNC([C@@H](N1C(C=CC1=O)=O)CNC(CCP(O)(O)=O)=O)=O)(O)=O)=O)CC(N[C@H]2CCOC2=O)=O)=O)C(N[C@H](C(NC3=CC=C(CO)C=C3)=O)CCCNC(N)=O)=O
|
|||||
| InChI |
InChI=1S/C45H68N10O22P2/c1-27(2)39(43(65)53-30(4-3-14-48-45(46)67)40(62)50-29-7-5-28(26-56)6-8-29)54-41(63)32(24-36(59)51-31-11-17-75-44(31)66)52-35(58)12-16-73-19-20-74-21-22-77-79(71,72)76-18-15-47-42(64)33(55-37(60)9-10-38(55)61)25-49-34(57)13-23-78(68,69)70/h5-10,27,30-33,39,56H,3-4,11-26H2,1-2H3,(H,47,64)(H,49,57)(H,50,62)(H,51,59)(H,52,58)(H,53,65)(H,54,63)(H,71,72)(H3,46,48,67)(H2,68,69,70)/t30-,31-,32-,33-,39-/m0/s1
|
|||||
| InChIKey |
JCANUVLKJKRYFB-LCBITFKISA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1163.035
|
Polar area
|
474.48
|
||
|
Complexity
|
2307.112441
|
xlogp Value
|
-3.8512
|
|||
|
Heavy Count
|
79
|
Rot Bonds
|
37
|
|||
|
Hbond acc
|
19
|
Hbond Donor
|
13
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
AU2023279443A1 Example A17 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
A mixed solvent of PBS and and Matrigel was used to prepare a cell suspension of 5.0x107 cells / mL. The prepared cell suspension was subcutaneously injected to the right flank region of female BALB/c-nu/nu mice at 0.1 mL per mouse. Individuals having a tumor volume within a range of 50 to 500 mm 3 were selected. test compound at a concentration of 3 mg/kg or the solvent alone was intravenously administered. the tumor volume was measured at Day 0 and Day 21.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87 female BALB/c-nu/nu mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition rate (%) | > 14% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell growth inhibition test was carried out on HER2-positive human gastric cancer cell line (NCI-N87), the cells were treated with a test compound or an anti-HER2 antibody (trastuzumab) at a concentration of 100 ng/mL. The cells were cultured for 6 days, then CellTiter-Glo was added and the luminescence amount was measured.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||